Fate Therapeutics Inc (NASDAQ: FATE)’s stock price has soared by 2.75% in relation to previous closing price of $1.09. Nevertheless, the company has seen a loss of -1.75% in its stock price over the last five trading days. globenewswire.com reported 2025-07-03 that SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share of $1.12, which was the closing price per share of the Company’s common stock as reported by NASDAQ on July 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 37,900 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
Is It Worth Investing in Fate Therapeutics Inc (NASDAQ: FATE) Right Now?
The 36-month beta value for FATE is also noteworthy at 2.24. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for FATE is 107.09M, and at present, short sellers hold a 8.88% of that float. The average trading volume of FATE on July 09, 2025 was 1.99M shares.
FATE’s Market Performance
FATE’s stock has seen a -1.75% decrease for the week, with a -30.00% drop in the past month and a 23.16% gain in the past quarter. The volatility ratio for the week is 6.89%, and the volatility levels for the past 30 days are at 10.20% for Fate Therapeutics Inc The simple moving average for the last 20 days is -7.11% for FATE’s stock, with a simple moving average of -34.59% for the last 200 days.
Analysts’ Opinion of FATE
Piper Sandler, on the other hand, stated in their research note that they expect to see FATE reach a price target of $6, previously predicting the price at $4. The rating they have provided for FATE stocks is “Overweight” according to the report published on June 17th, 2024.
Wells Fargo gave a rating of “Equal Weight” to FATE, setting the target price at $6 in the report published on March 27th of the previous year.
FATE Trading at -7.03% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.08% of loss for the given period.
Insider Trading
Bressi Jerome Charles, the of Fate Therapeutics Inc, sale 5,980 shares at $1.55 during a trade that took place back on Jan 10 ’25, which means that Bressi Jerome Charles is holding 270,203 shares at $9,269 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -15.03 for the present operating margin
- -1.59 for the gross margin
The net margin for Fate Therapeutics Inc stands at -13.19. The total capital return value is set at -0.54. Equity return is now at value -49.23, with -36.32 for asset returns.
Based on Fate Therapeutics Inc (FATE), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.48.
Currently, EBITDA for the company is -176.58 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 12.59. The receivables turnover for the company is 5.54for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.81.
Conclusion
In summary, Fate Therapeutics Inc (FATE) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
